Identification of Small Molecules with Type I Interferon Inducing Properties by High-Throughput Screening

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Martínez Gil, Luis ^a   Ayllon, Juan ^a   Ortigoza, Mila Brum ^a   García Sastre, Adolfo ^a   Shaw, Megan L ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (DIETHYLAMINO)ETHYL] 2,3 DIAZATETRACYCLO [7.6.1.0.(5,16), 0(10,15)]HEXADECA 1,5 (16),6,8,10,12,14, HEPTAEN 4 ONE; 3,10 DIAZAPENTACYCLO[10.7.1.0(2,11).0(4,9).0(16,20)]ICOSA 1(19),2,4,6,8,10,12,14,16(20),17 DECAENE 6 SULFONAMIDE; ANTIVIRUS AGENT; BETA INTERFERON; CASPASE 3; INTERFERON; N1,N1 DIMETHYL N2 [2 (THIENYL) 4 QUINOLYL] 1,2 ETHANEDIAMINE; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 PROTEINASE; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4A PROTEINASE; PROTEINASE; UNCLASSIFIED DRUG; INS1 PROTEIN, INFLUENZA VIRUS; MOLECULAR LIBRARY; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ADJUVANT THERAPY; ANIMAL CELL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; ENZYME ACTIVITY; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; VACCINATION; ANIMAL; CELL LINE; DRUG EFFECTS; EPITHELIUM CELL; HEK293 CELL LINE; LUNG; METABOLISM; MOLECULAR LIBRARY; MOUSE; PHARMACOLOGY; PROCEDURES; VERO CELL LINE;

HEPATITIS C VIRUS; INFLUENZA A VIRUS; MURINAE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; EPITHELIAL CELLS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERFERON TYPE I; LUNG; MICE; SMALL MOLECULE LIBRARIES; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84868705366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049049     Document Type: Article

References (52)

1. Keam SJ, Cvetković RS, (2008) Peginterferon-alpha-2a (40 kd) plus ribavirin: a review of its use in the management of chronic hepatitis c mono-infection. Drugs 68: 1273-1317.
2. Bergman SJ, Ferguson MC, Santanello C, (2011) Interferons as therapeutic agents for infectious diseases. Infect Dis Clin North Am 25: 819-834.
3. Falcoff E, Falcoff R, Cherby J, Florent J, Lunel J, et al. (1973) Double-stranded ribonucleic acid from mengo virus: production, characterization, and interferon-inducing and antiviral activities in comparison with polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother 3: 590-598.
4. Field AK, Tytell AA, Lampson GP, Hilleman MR, (1967) Inducers of interferon and host resistance. ii. multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A 58: 1004-1010.
5. Panter G, Kuznik A, Jerala R, (2009) Therapeutic applications of nucleic acids as ligands for toll-like receptors. Curr Opin Mol Ther 11: 133-145.
6. Miller RL, Meng T, Tomai MA, (2008) The antiviral activity of toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21: 69-87.
7. Toporovski R, Morrow MP, Weiner DB, (2010) Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther 10: 1489-1500.
8. Rizza P, Capone I, Moretti F, Proietti E, Belardelli F, (2011) Ifn-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev Vaccines 10: 487-498.
9. Prchal M, Pilz A, Simma O, Lingnau K, von Gabain A, et al. (2009) Type i interferons as mediators of immune adjuvants for t- and b cell-dependent acquired immunity. Vaccine 27Suppl 6: G17-20.
10. Tovey MG, Lallemand C, (2010) Adjuvant activity of cytokines. Methods Mol Biol 626: 287-309.
11. Kuznik A, Panter G, Jerala R, (2010) Recognition of nucleic acids by toll-like receptors and development of immunomodulatory drugs. Curr Med Chem 17: 1899-1914.
12. Martinez-Martin N, Viejo-Borbolla A, (2010) Toll-like receptor-mediated recognition of herpes simplex virus. Front Biosci (Schol Ed) 2: 718-729.
13. Klein Klouwenberg P, Tan L, Werkman W, van Bleek GM, Coenjaerts F, (2009) The role of toll-like receptors in regulating the immune response against respiratory syncytial virus. Crit Rev Immunol 29: 531-550.
14. Baum A, Sachidanandam R, García-Sastre A, (2010) Preference of rig-i for short viral rna molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A 107: 16303-16308.
15. Loo Y, Gale MJ, (2011) Immune signaling by rig-i-like receptors. Immunity 34: 680-692.
16. Kumar H, Kawai T, Akira S, (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30: 16-34.
17. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The rna helicase rig-i has an essential function in double-stranded rna-induced innate antiviral responses. Nat Immunol 5: 730-737.
18. Miller DK, Lenard J, (1982) Ultraviolet-irradiated vesicular stomatitis virus and defective-interfering particles are similar non-specific inhibitors of virus infection. J Gen Virol 60: 327-333.
19. Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M, (1995) Prophylactic and therapeutic efficacies of poly(ic.lc) against respiratory influenza a virus infection in mice. Antimicrob Agents Chemother 39: 2574-2576.
20. Herniman KA, Sellers RF, (1972) Protection of guinea-pigs against foot-and-mouth disease by simultaneous inoculation of sendai virus and inactivated foot-and-mouth disease vaccine. Arch Gesamte Virusforsch 37: 97-103.
21. Nagarajan U, (2011) Induction and function of ifnβ during viral and bacterial infection. Crit Rev Immunol 31: 459-474.
22. Barber GN, (2011) Innate immune dna sensing pathways: sting, aimii and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 23: 10-20.
23. Cavlar T, Ablasser A, Hornung V, (2012) Induction of type i ifns by intracellular dna-sensing pathways. Immunol Cell Biol 90(5): 474-82.
24. Hai R, Martínez-Sobrido L, Fraser KA, Ayllon J, García-Sastre A, et al. (2008) Influenza b virus ns1-truncated mutants: live-attenuated vaccine approach. J Virol 82: 10580-10590.
25. Nguyen DN, Kim P, Martínez-Sobrido L, Beitzel B, García-Sastre A, et al. (2009) A novel high-throughput cell-based method for integrated quantification of type i interferons and in vitro screening of immunostimulatory rna drug delivery. Biotechnol Bioeng 103: 664-675.
26. Hoffmann H, Kunz A, Simon VA, Palese P, Shaw ML, (2011) Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108: 5777-5782.
27. Zhang J, Chung T, Oldenburg K, (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
28. Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC, (2006) Inhibition of the type i interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80: 9192-9199.
29. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M, (1998) Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 188: 2091-2097.
30. Strahle L, Garcin D, Kolakofsky D, (2006) Sendai virus defective-interfering genomes and the activation of interferon-beta. Virology 351: 101-111.
31. Desmyter J, Melnick JL, Rawls WE, (1968) Defectiveness of interferon production and of rubella virus interference in a line of african green monkey kidney cells (vero). J Virol 2: 955-961.
32. Emeny JM, Morgan MJ, (1979) Regulation of the interferon system: evidence that vero cells have a genetic defect in interferon production. J Gen Virol 43: 247-252.
33. Ortigoza MB, Dibben O, Maamary J, Martinez-Gil L, Leyva-Grado VH, et al. (2012) A novel small molecule inhibitor of influenza a viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog 8: e1002668.
34. Meyer O, (2009) Interferons and autoimmune disorders. Joint Bone Spine 76: 464-473.
35. Cheng Y, Xu F, (2011) Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 10: 1219-1223.
36. Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, et al. (2012) Unique moe-dna chimeric oligonucleotide induces an atypical mda5 dependent induction of type i interferon response. J Pharmacol Exp Ther:.
37. Liu F, Gu J, (2011) Retinoic acid inducible gene-i, more than a virus sensor. Protein Cell 2: 351-357.
38. Rayet B, Gélinas C, (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.
39. Hale BG, Albrecht RA, García-Sastre A, (2010) Innate immune evasion strategies of influenza viruses. Future Microbiol 5: 23-41.
40. Loo Y, Owen DM, Li K, Erickson AK, Johnson CL, et al. (2006) Viral and therapeutic control of ifn-beta promoter stimulator 1 during hepatitis c virus infection. Proc Natl Acad Sci U S A 103: 6001-6006.
41. Wang BX, Fish EN, (2012) The yin and yang of viruses and interferons. Trends Immunol 33: 190-197.
42. Inao T, Harashima N, Monma H, Okano S, Itakura M, et al. (2011) Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(i:c), on human breast cancer. Breast Cancer Res Treat: 134 (1): 89-100.
43. Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K, et al. (2011) A possible anticancer agent, type iii interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol 2011: 479013.
44. Bedard KM, Wang ML, Proll SC, Loo Y, Katze MG, et al. (2012) Isoflavone agonists of irf-3 dependent signaling have antiviral activity against rna viruses. J Virol 86: 7334-7344.
45. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ, (2012) High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS ONE 7: e36594.
46. Versteeg GA, García-Sastre A, (2010) Viral tricks to grid-lock the type i interferon system. Curr Opin Microbiol 13: 508-516.
47. Cheng B, Liu I, Tse-Dinh Y, (2007) Compounds with antibacterial activity that enhance dna cleavage by bacterial dna topoisomerase i. J Antimicrob Chemother 59: 640-645.
48. Tang SC, Shapiro TA, (2010) Newly identified antibacterial compounds are topoisomerase poisons in african trypanosomes. Antimicrob Agents Chemother 54: 620-626.
49. Wheeler HR, Geczy CL, (1990) Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer 46: 626-632.
50. Kim T, Kim TY, Song YH, Min IM, Yim J, et al. (1999) Activation of interferon regulatory factor 3 in response to dna-damaging agents. J Biol Chem 274: 30686-30689.
51. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, et al. (2012) Antiviral resistance during the 2009 influenza a h1n1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 12: 240-248.
52. Farci P, (2011) New insights into the hcv quasispecies and compartmentalization. Semin Liver Dis 31: 356-374.